Development of Population Norms of the Computerized Neuropsychological Assessment for Effectiveness of the Antipsychotic Treatment in Schizophrenia

Schizophrenia Clinical Trial

Official title:

Development of Population Norms of the Computerized Neuropsychological Assessment for Effectiveness of the Antipsychotic Treatment in Schizophrenia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00789906
• Other study ID #: 223CTIL
• Status: Recruiting
• Phase: N/A
• First received: November 11, 2008
• Last updated: November 12, 2008
• Start date: July 2008

Study information

• Verified date: November 2008
• Source: BeerYaakov Mental Health Center
• Contact: Semyon Kertzman, MD
• Phone: 972-8-9776136
• Email: research[@]beerness.health.gov.il
• Is FDA regulated: No
• Health authority: Israel: Ministry of Health
• Study type: Observational

Clinical Trial Summary

Schizophrenia affects cognition, emotion, and behavior. Neuropsychological assessment enables a better understanding of antipsychotic effectiveness and the brain processes, underlying cognitive functioning in schizophrenia.

Neurocognitive deficits in schizophrenia patients appears to explain up to 61% of the variance of functional outcome and is an important predictor of social reintegration (Peuskens et al, 2005) and independent living activitiy (Green et al, 2004). Impaired social functioning within schizophrenia population has been associated with increased health-care costs. Since social and occupational disability may generate the largest indirect costs of the illness, treatment of cognitive deficits has an enormous impact on the cost and disability associated with schizophrenia (McGurk and Mueser, 2004).

However, the gap between cognitive science and clinical practice limits the implementation of cognitive assessment in the routine evaluation of schizophrenia patients. Pharmaceutical industry initiated numerous large scale, multisite studies on the impact of novel antipsychotics on cognitive deficits in schizophrenia patients.

The aim of this research is to develop population norms of the computerized neuropsychological assessment for effectiveness of the antipsychotic treatment in schizophrenia.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 700
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 89 Years

Eligibility

Inclusion Criteria:

• An IQ, which is within normal range.

Exclusion Criteria:

• Psychiatric co-morbidity.

• Physical disability or illness.

• A history of severe head injury.

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Schizophrenia

Locations

Country	Name	City	State
Israel	Beer-Yaacov MHC	Beer Yaacov

Sponsors (1)

Lead Sponsor	Collaborator
BeerYaakov Mental Health Center

Country where clinical trial is conducted

Israel,